Development of inducible genetic systems to finely tune efficacy of InhA-targeting anti-tuberculous drugs
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a leading global health threat, especially due to multidrug-resistant strains. The first-line drug isoniazid (INH) and second-line drugs ethionamide (ETH) and prothionamide (PTH), are prodrugs that target the essential enoyl-ACP reductase InhA, a key enzyme involved in mycolic acid biosynthesis. Resistance to these drugs…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
